Literature DB >> 8808680

Cytotoxic T cell-resistant variants are selected in a virus-induced demyelinating disease.

L Pewe1, G F Wu, E M Barnett, R F Castro, S Perlman.   

Abstract

C57BI/6 mice infected with mouse hepatitis virus, strain JHM (MHV-JHM) develop a chronic demyelinating encephalomyelitis. Infectious virus can be isolated only from symptomatic mice. In C57BI/6 mice, two CD8+ T cell epitopes within the MHV-JHM surface glycoprotein were previously identified. Here, we show that mutations in the RNA encoding the immunodominant of the epitopes are present in nearly all virus samples isolated from these mice. Mutations are not present in sequences flanking this epitope or in other CD8+ or CD4+ T cell epitopes. Furthermore, analysis of five peptides corresponding to variant epitopes in direct ex vivo cytotoxicity assays showed that each mutation caused a loss of epitope recognition. These results suggest that escape from CD8+ T cell recognition is necessary for enhanced virus replication and development of clinical disease in these MHV-JHM-infected mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808680     DOI: 10.1016/s1074-7613(00)80320-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  42 in total

1.  Generation of coronavirus spike deletion variants by high-frequency recombination at regions of predicted RNA secondary structure.

Authors:  C L Rowe; J O Fleming; M J Nathan; J Y Sgro; A C Palmenberg; S C Baker
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Major histocompatibility complex controls the trajectory but not host-specific adaptation during virulence evolution of the pathogenic fungus Cryptococcus neoformans.

Authors:  Erin E McClelland; Frederick R Adler; Donald L Granger; Wayne K Potts
Journal:  Proc Biol Sci       Date:  2004-08-07       Impact factor: 5.349

3.  Cytotoxic T-cell-resistant variants arise at early times after infection in C57BL/6 but not in SCID mice infected with a neurotropic coronavirus.

Authors:  L Pewe; S Xue; S Perlman
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  Functional management of an antiviral cytotoxic T-cell response.

Authors:  M F Bachmann; D E Speiser; P S Ohashi
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 6.  Murine coronavirus infection: a paradigm for virus-induced demyelinating disease.

Authors:  T E Lane; M J Buchmeier
Journal:  Trends Microbiol       Date:  1997-01       Impact factor: 17.079

7.  Contributions of the viral genetic background and a single amino acid substitution in an immunodominant CD8+ T-cell epitope to murine coronavirus neurovirulence.

Authors:  Katherine C MacNamara; Ming Ming Chua; Joanna J Phillips; Susan R Weiss
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein.

Authors:  Evelena Ontiveros; Taeg S Kim; Thomas M Gallagher; Stanley Perlman
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  A severe acute respiratory syndrome-associated coronavirus-specific protein enhances virulence of an attenuated murine coronavirus.

Authors:  Lecia Pewe; Haixia Zhou; Jason Netland; Chandra Tangudu; Heidi Olivares; Lei Shi; Dwight Look; Thomas Gallagher; Stanley Perlman
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.

Authors:  Jason Netland; Marta L DeDiego; Jincun Zhao; Craig Fett; Enrique Álvarez; José L Nieto-Torres; Luis Enjuanes; Stanley Perlman
Journal:  Virology       Date:  2010-01-27       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.